GW9508 is primarily used in research settings as a selective agonist for the free fatty acid receptors FFAR1 (GPR40) and FFAR4 (GPR120). It is particularly valuable in studying the role of these receptors in metabolic processes, such as glucose homeostasis and insulin secretion. Researchers utilize GW9508 to explore its potential therapeutic applications in managing type 2 diabetes and obesity, as it can enhance insulin release and improve glucose tolerance. Additionally, it is employed in investigations related to inflammation and fatty acid metabolism, providing insights into its effects on cellular signaling pathways. Its application extends to drug discovery efforts aimed at developing novel treatments for metabolic disorders.